Implementing lipid optimisation through prescribing strategies to reduce cardiovascular risk
Supporting information
See the following resources for more information:
-
Quality and outcomes framework guidance for 2023/24, Version 2, January 2024
-
Nitsch D, Caplin B, Hull SA, et al. (2017) National Chronic Kidney Disease Audit: National Report (Part 1). Healthcare Quality Improvement Partnership (HQIP)
-
BOB ICB primary care inclisiran resource pack (PowerPoint)
Quotes
"We have worked with primary care healthcare professionals to highlight the range of cholesterol treatments available and how they can help their patients better understand their risk factors and manage their cholesterol levels through treatment plans more effectively."
Janice Craig, Medicines Optimisation Lead Pharmacist, BOB ICB.
"We have worked closely with the Health Innovation Network (HIN) and made a particular effort to reach people who might be at risk of CVD and not yet receiving help. The HIN has created leaflets, posters and videos. We have shared this far and wide, from being played in GP surgeries to mental health teams. We have translated leaflets into other languages spoken in our area."
Dr Heike Veldtman, GP and CVD Lead, BOB ICB.
Contact details
Janice Craig
Medicines Optimisation Lead Pharmacist, NICE Medicines and Prescribing Associate
Email: Janice.Craig@nhs.net
ISBN: 978-1-4731-9441-0
This page was last updated: